Johnson & Johnson complete friendly takeover of Crucell

Feb 22, 2011

Pharmaceutical and health care giant Johnson & Johnson announced Tuesday the successful completion of a friendly takeover of Dutch vaccine maker Crucell, for about 1.75 billion euros ($2.37 billion).

"Johnson & Johnson and Crucell today announce that Johnson & Johnson has completed the tender offer for Crucell," the companies said in a joint statement.

Johnson & Johnson, which employs 114,000 people, has said it intends to retain Crucell's management and staff and to keep the headquarters at Leiden in the western Netherlands.

Johnson & Johnson, which now owns more than 95 percent of Crucell's capital announced a supplementary offer period from Wednesday until March 8.

The health care giant first announced its intention to buy up Crucell last October for 24.75 euros per share.

The European Commission authorised the late last month, seeing no competition problems.

Crucell, which employs 1,300 people, produced more than 115 million doses of vaccine in 2009 for distribution in about 100 countries, mostly developing nations.

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Johnson & Johnson, Crucell biotech announce takeover

Oct 06, 2010

Pharmaceutical and health care giant Johnson & Johnson has reached a deal with Dutch biotechnology vaccine group Crucell to buy 82.5 percent of Crucell for about 1.75 billion euros, the two firms said on Wednesday.

Summer time and the living is breezy

Jun 06, 2006

The U.S. hurricane season is under way and for many people in areas hit hard by 2005's hurricanes, it's going to be an uneasy summer.

Farmers relying on roundup lose some of its benefit

Apr 14, 2009

(PhysOrg.com) -- Roundup Ready crops have made weed control much easier for farmers, but a new study shows their reliance on the technology may be weakening the herbicide's ability to control weeds.

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

1 hour ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.